StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.72−0.16 (-8.51%)

Close on Nov 18, 2026Market cap $6.14MP/E –Yield 959.30%

Cadrenal Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Cadrenal Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$10.16M. For fiscal 2025 it was -$12.60M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.60M–
FY2024Dec 31, 2024-$7.36M–
FY2023Dec 31, 2023-$3.53M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.23M–
Q1 FY2026Mar 31, 2026-$3.00M–
Q4 FY2025Dec 31, 2025-$2.57M–
Q3 FY2025Sep 30, 2025-$2.36M–
Q2 FY2025Jun 30, 2025-$3.03M–
Q1 FY2025Mar 31, 2025-$4.65M–
Q4 FY2024Dec 31, 2024-$1.79M–
Q3 FY2024Sep 30, 2024-$2.20M–
Q2 FY2024Jun 30, 2024-$1.53M–
Q1 FY2024Mar 31, 2024-$1.84M–
Q4 FY2023Dec 31, 2023-$694.45K–
Q1 FY2023Mar 31, 2023-$1.41M–

More Cadrenal Therapeutics figures

See a number that looks wrong?